
    
      The PDS-2™ System is intended to reduce coronary atheroma in patients with Homozygous
      Familial Hypercholesterolemia (HoFH). Subjects will receive serial infusions of autologous
      selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics' PDS-2
      System.
    
  